Pictured: Yu Chen

Yu Chen, MD, PhD

Medical Oncologist

Titles

Associate Attending Physician

Clinical Expertise

Prostate Cancer; Bladder Cancer

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Chen accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Cornell University Medical College

Residencies

Internal Medicine - Brigham and Women's Hospital

Fellowships

Medical Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine, Medical Oncology

As a physician-scientist and board-certified medical oncologist. I am devoted to the care of cancer patients in the clinic and to gaining knowledge in the laboratory of how cancers develop. My research focus is on the pathogenesis and treatment of prostate cancer. I am involved in a multidisciplinary effort with oncologists, pathologist, and surgeons to analyze tumor tissues and to develop clinical trials. My laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on the study of critical drivers in prostate cancer pathogenesis using cell, tissue, and mouse models.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Genitourinary Oncology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Chen's Lab

Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P.. Visualization of the interstitial cells of cajal (ICC) network in mice. J Vis Exp Dec 31, 2011; 53 :

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.. Cancer Cell 2011; 19 :575-86

Chen Y., Arora, V.K. Sawyers C.L. (2011). Molecular Biology of Prostate Cancer. In: Devita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia: Lippincott Williams & Wilkins.

Read more

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010; 467 :849-53

Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.. Cancer Cell 2010; 17 :415-6

Chen Y, Clegg NJ, Scher HI.. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology 2009; 10 :981-91

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.. Science 2009; 324 :787-90

Welsbie D, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 2009; 69 :958-66

Chen Y, Sawyers CL, Scher HI.. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 :440-448

Chen Y, Sawyers CL. Molecular Biology of Prostate Cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1385-91.

Ghia KK, Chen Y, Milner DA Jr, Fisher DC. Challenging manifestations of malignancies. Case 2. Langerhans cell histiocytosis presenting with a skin rash.. Journal of Clinical Oncology 2004; 22 :3640-3642

Rajagopal A, Pant AC, Simon SM, Chen Y.. In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.. Cancer Research 2002; 62 :391-396

Chen Y, Pant AC, Simon SM.. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.. Cancer Research 2001; 61 :391-396

Chen Y, Simon SM.. In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.. The Journal of Cell Biology 2000; 148 :863-879

Chen Y, Schindler M, Simon SM.. A mechanism for tamoxifen-mediated inhibition of acidification. Journal of Biological Chemistry 1999; 274 :18364-18373

Altan N, Chen Y, Schindler M, Simon SM.. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. . Proceedings of the National Academy of Sciences of the United States of America 1999; 96 :44432-4438

Altan N, Chen Y, Schindler M, Simon SM.. Defective acidification in human breast tumor cells and implications for chemotherapy. Journal of Experimental Medicine 1998; 187 :1583-1598

Chen Y, Gross P, Ramakrishna V, Rabitz H, Mease K, Singh H. Control of classical regime molecular objectives - applications of tracking and Variations of the theme. Automatica 1997; 33 :1617-1633

Chen Y., Gross P., Ramakrishn V., Rabitz H., Mease K., Singh H. Selective excitation of molecular eigenstates using state-dependent optical field design. Chemical Physics Letters 1996; 252 :447-456

Chen Y, Gross P, Ramakrishna V, Rabitz H., Mease K, Singh H. Competitive tracking of molecular objectives described by quantum mechanics. Journal of Chemical Physics 1995; 102 :8001-8010

 

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yu Chen discloses the following relationships and financial interests:

  • Merck & Co Inc.
    Provision of Services
  • Myovant Sciences
    Ownership / Equity Interests
  • Oric Pharmaceuticals
    Intellectual Property Rights; Ownership / Equity Interests

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures